Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reducing Fatigue With CoQ10 in Crohn's Disease
NCT06419335Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jul 2024
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of coenzyme q10 in Crohn's disease (3 cohorts), sponsored by University of Pennsylvania. Primary endpoint: Assess improved fatigue among patients with Crohn's Disease at 8 weeks. Started Jul 2024; status: active, not recruiting.
02
Drugs
coenzyme q10
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT06419335.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06419335.